Guggenheim on Larimar (LRMR): 'With multiple near-term catalysts on the horizon, we see substantial upside potential'
Tweet Send to a Friend
Guggenheim analyst Yatin Suneja reiterated a Buy rating and $26.00 price target on Larimar Therapeutics (NASDAQ: LRMR).The analyst comments "Following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
